Research Disclaimer: All compounds described are sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.
Ipamorelin, GHRP-6, and GHRP-2 are all synthetic growth hormone secretagogue peptides that activate the ghrelin receptor (GHSR-1a) to stimulate GH release from pituitary somatotrophs. While their primary mechanism of action is shared, their off-target receptor activities differ substantially — producing distinct side-effect profiles that significantly affect research design and compound selection.
Structural Overview#
| Compound | Structure | Residues | MW |
|---|---|---|---|
| Ipamorelin | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | 5 (pentapeptide) | 711.9 Da |
| GHRP-6 | His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 | 6 (hexapeptide) | 873.0 Da |
| GHRP-2 | D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 | 6 (hexapeptide) | 817.9 Da |
All three are synthetic small peptides that mimic the core pharmacophore of ghrelin (endogenous 28-AA peptide) needed for GHSR-1a activation. The structural differences affect receptor selectivity profiles.
GHSR-1a Potency Comparison#
In vitro GHSR-1a binding data:
- GHRP-2: EC50 ~0.3 nM — strongest GHSR-1a potency of the three
- Ipamorelin: EC50 ~4.2 nM — moderate GHSR-1a potency
- GHRP-6: EC50 ~0.7 nM — intermediate potency
Peak GH release (equimolar in vivo comparison): GHRP-2 > GHRP-6 ≈ Ipamorelin (at equimolar doses)
However: Raw GH peak amplitude is not the only relevant metric — the off-target hormone profiles are equally important for research validity.
The Critical Difference: Off-Target Receptor Activity#
Cortisol release:
- GHRP-2: significant ACTH and cortisol stimulation (CRH-like activity at hypothalamus)
- GHRP-6: moderate cortisol and prolactin stimulation
- Ipamorelin: minimal cortisol and minimal prolactin elevation
Appetite stimulation:
- GHRP-6: strongest appetite stimulation (ghrelin-like; acts on hypothalamic NPY neurons)
- GHRP-2: moderate appetite stimulation
- Ipamorelin: minimal appetite stimulation
Prolactin:
- GHRP-2: significant prolactin release
- GHRP-6: moderate prolactin release
- Ipamorelin: minimal prolactin release
Research Implications of Off-Target Activity#
Why cortisol confounds GH research:
If a GH secretagogue also stimulates cortisol:
- Cortisol is catabolic → counteracts anabolic effects of GH/IGF-1
- Cortisol independently affects body composition, glucose, and inflammation
- GH+cortisol mixed effects make it impossible to attribute outcomes to GH alone
- Example: GHRP-2 at high dose may produce a larger GH peak but simultaneously raise cortisol → net effect on body composition may be less beneficial than ipamorelin despite higher GH peak
Ipamorelin's selectivity advantage: Ipamorelin was specifically designed for GHSR-1a selectivity with minimal off-target receptor activity. Published selectivity data (Raun et al., Eur J Endocrinol 1998): ipamorelin produced GH release equivalent to GHRP-6 at similar doses while ACTH/cortisol remained at baseline.
When off-target activity is the research question:
- GHRP-6's appetite effect: ideal for hunger/ghrelin biology research; isolates appetite-GH connection
- GHRP-2 cortisol effect: useful for modeling stress-hormone interactions with GH
- Ipamorelin: ideal when GH axis is the sole research variable
Protocol Suitability#
| Research question | Recommended compound |
|---|---|
| Clean GH pulse characterization | Ipamorelin — minimal off-target confounds |
| Maximum GH peak amplitude research | GHRP-2 — highest potency; accept cortisol confound |
| Appetite/ghrelin system research | GHRP-6 — strongest ghrelin-like appetite effects |
| Long-acting IGF-1 elevation | Ipamorelin + CJC-1295 DAC combination |
| Stress-GH interaction studies | GHRP-2 (raises both GH and ACTH) |
| Combination: pulsatile GH study | Ipamorelin (twice daily) + CJC-1295 DAC (weekly) |
Typical Research Dosing#
| Compound | Rodent research dose | Route | Frequency |
|---|---|---|---|
| Ipamorelin | 100–300 µg/kg | SC | Twice daily |
| GHRP-6 | 100–300 µg/kg | SC | Twice daily |
| GHRP-2 | 100–300 µg/kg | SC | Twice daily |
All three: peak GH within 15–30 min; return to baseline by 90–120 min; no sustained IGF-1 elevation without concurrent CJC-1295 DAC.
Summary#
Ipamorelin is the preferred choice for research that specifically investigates the GH/IGF-1 axis without cortisol, appetite, or prolactin confounds. GHRP-2 is preferred when maximum GH peak amplitude is the priority. GHRP-6 is preferred when ghrelin-like appetite effects are part of the research question. Understanding these differences is essential for valid research design and meaningful data interpretation.
Research Use Only. JuicedPharma does not provide medical advice.
Published by JuicedPharma Research Team · September 2026 · Category: Growth Hormone
